Machine learning is driving efforts to classify MS into distinct subtypes that may predict disease course, but two experts debate whether this will advance patient care.

Synthetic biology specialist GRO Biosciences is exploring strategic alternatives about six months after raising a series B ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

The decision comes just a few months after Bayer reported encouraging results for eliapixant in chronic cough – the same indication sought by Merck for gefapixant – saying it hit its objective ...

Detailed price information for Verizon Communications Inc (VZ-N) from The Globe and Mail including charting and trades.

Refractory chronic cough is a cough that persists for over 8 weeks and does not respond to treatment of any underlying cause. Recent randomised trials for refractory chronic cough have shown ...

Only seven countries met World Health Organization (WHO) air quality standards last year, data showed on Tuesday, as ...

Bayer says its drug candidate for chronic cough – eliapixant – has hit the mark in a phase 2b trial, putting it in hot pursuit of Merck & Co's gefapixant, which was filed for approval in March.

For baby boomers, ultra-safe dividend stocks like these five that can add passive income streams to Social Security benefits.